On February 7, 2023 Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, reported dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in patients with advanced solid tumors (Press release, Immix Biopharma, FEB 7, 2023, View Source [SID1234626918]). Initial clinical data from this combination trial is anticipated to be released on a rolling basis beginning in 1H 2023. IMX-110 + Beigene/Novartis anti-PD-1 tislelizumab combination treatment is designed to enhance response to solid tumors by turning immunologically "cold" tumors "hot". In ImmixBio prior IMX-110 + anti-PD-1 preclinical experiments, a 50% improvement (63-day median survival) was produced by IMX-110 + anti-PD-1 in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system, compared to a 4-drug combination of 2 chemotherapies and 2 immunotherapies (anti-PD-1/anti-CD40/nab-paclitaxel/gemcitabine) in the same genetic pancreatic cancer mouse model (42-day median survival) according to Winograd et al., 2015.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are thrilled to kick-off this important milestone working with our partner BeiGene," said Ilya Rachman, MD PhD, CEO of ImmixBio. "We believe the combination of IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab will have a synergistic effect that could bolster responses and expand the population of cancer patients benefiting from these therapies."
About IMX-110
The U.S. Food and Drug Administration ("FDA") approved orphan drug designation ("ODD") for IMX-110 in soft tissue sarcoma. The FDA also approved Rare Pediatric Disease Designation ("RPDD") for IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening form of cancer in children. RPDD qualifies Immix Biopharma to receive fast track review, and a priority review voucher ("PRV") at the time of marketing approval of IMX-110. PRV holders can benefit from an expedited six-month review of a new drug application for any disease by the FDA. IMX-110 is currently being evaluated in a phase 1b/2a clinical trial in patients with advanced solid tumors. Learn more at www.immixbio.com/iMX-110